Ovid will discontinue development of OV101 (**oxadol), a delta (δ-selective **AA receptor agonist, in Angelman syndrome. Furthermore, Ovid does not plan to initiate further clinical studies of OV101 in Fragile X syndrome
https://investors.ovidrx.com/news-r...s-update-ov101-program-and-prioritization-its
OVID FAIL, page-9
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.23 |
Change
-0.270(1.38%) |
Mkt cap ! $2.468B | |||
| Open | High | Low | Value | Volume |
| $19.50 | $19.59 | $19.19 | $3.248M | 167.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 131 | $19.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.23 | 133 | 6 |
View Market Depth
| Last trade - 14.07pm 10/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |